Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the US Market

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the US Market

By, Admin 8 March 2025

Global pharma major Lupin Limited (Lupin) announced that it has launched rivaroxaban tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the US FDA.

Rivaroxaban tablets USP, 2.5 mg, is bioequivalent to Xarelto tablets, 2.5 mg of Janssen Pharmaceuticals, Inc., and indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD); to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD.

Rivaroxaban tablets USP, 2.5 mg (RLD Xarelto) had estimated annual sales of USD 446 million in the US (IQVIA MAT January 2025).

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!